Peptic Ulcer Drugs Market Outlook - 2028

Due to the COVID-19 pandemic, the global Peptic Ulcer Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of 3.8% during the review period.

Fully considering the economic change by this health crisis, by Type accounting for % of the Peptic Ulcer Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While by Type segment is altered to an % CAGR throughout this forecast period.

The main global Peptic Ulcer Drugs players include Takeda Pharmaceutical, AstraZeneca, Pfizer, Teva Pharmaceuticals, EA Pharma, etc. The top five Peptic Ulcer Drugs players account for approximately 43% of the total market. United States is the largest consumer market for Peptic Ulcer Drugs, accounting for about 30%, followed by Europe and China. In terms of type, Proton Pump Inhibitors is the largest segment, with a share over 68%. And in terms of application, the largest application is Hospital and Clinic, followed by Drugstore.

Peptic Ulcer Drugs Market Scope and Market Size

The global Peptic Ulcer Drugs market is segmented by company, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Peptic Ulcer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

Segment by Type

• Proton Pump Inhibitors
• H2-Antagonists
• Antacids
• Others

Segment by Application

• Hospital and Clinic
• Drugstore

By Region

• United States
• Europe
• China
• Japan
• Southeast Asia
• India
• Other Regions

By Company

• Takeda Pharmaceutical
• AstraZeneca
• Pfizer
• Teva Pharmaceuticals
• EA Pharma
• ASK Pharm
• Luoxin Pharmaceutical
• Abbott Laboratories
• Yuhan Pharmaceutical
• Daewoong Pharmaceutical